verified SJR 0,831 · Q2 • database Scopus / SJR & Web of Science & DOAJ indexed

United Kingdom · John Wiley and Sons Inc

workspace_premium Q2 — Medicine (miscellaneous) verified Plan S Compliant visibility_off Single blind Peer Review lock_open Open Access · DOAJ

Cardiovascular Therapeutics

Cardiovascular Therapeutics is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology with an H index of 59. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 1440 €. The scope of the journal is focused on cardiovascular pharmacology, cardiovascular drugs, cardiovascular diseases. It has an SJR impact factor of 0,831 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,831.

ISSN: 1755-5914

Publisher: John Wiley and Sons Inc

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,831 Q2

H-index 59

Acceptance rate pie_chart

31%

Source Acceptance_Rate

Time to publication hourglass_top

19 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

1.440 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

0,831

H-index

Docs (year)

Docs 3y

138

Total refs

1219

Cites 3y

486

Citable 3y

138

Cites/Doc 2y

3.64

Ref/Doc

34.83

Immediate OA

1440 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Bridging of Chronic Oral Anticoagulation with Enoxaparin in Patients with Atrial Fibrillation: Results from the Prospective BRAVE Registry

Zofenopril Plus Hydrochlorothiazide Fixed Combination in the Treatment of Hypertension and Associated Clinical Conditions

Drug-induced hERG Block and Long QT Syndrome

Drug-Drug Noninteractions

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants

Differences in Medical Treatment of Chronic Coronary Heart Disease Patients According to Medical Specialities

Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery

Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice

Clinical Effects of Torasemide Prolonged Release in Mild-to-Moderate Hypertension: A Randomized Noninferiority Trial Versus Torasemide Immediate Release

Circulating Galectin-3 and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis

Cilostazol Does not Improve Peripheral Arterial Disease-Linked Oxidative Stress

Chronic Pantoprazole Administration and Ischemia-Reperfusion ArrhythmiasIn Vivoin Rats-Antiarrhythmic or Arrhythmogenic?

SHOW MORE ARTICLES

Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel

A Dosing Algorithm for Erythropoietin Alpha in Older Adults with Heart Failure and a Preserved Ejection Fraction

Bioinformatics Analyses of Differentially Expressed Genes Associated with Acute Myocardial Infarction

Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus

Autonomic Modulation by Electrical Stimulation of the Parasympathetic Nervous System: An Emerging Intervention for Cardiovascular Diseases

Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients

Assessment of Arterial Stiffness, A Translational Medicine Biomarker System for Evaluation of Vascular Risk

Antihypertensive Drugs and New-Onset Diabetes: A Retrospective Longitudinal Cohort Study

Anacetrapib: Hope for CETP Inhibitors?

Allopurinol Treatment Reduces Arterial Wave Reflection in Stroke Survivors

Aliskiren in the Treatment of Hypertension and Organ Damage

Administration of Antiarrhythmic Drugs to Maintain Sinus Rhythm After Catheter Ablation for Atrial Fibrillation: A Meta-Analysis

FAQs

Cardiovascular Therapeutics has an SJR of 0,831 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 1440 EUR.

The acceptance rate recorded for Cardiovascular Therapeutics is 31%.

Cardiovascular Therapeutics

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Cardiovascular Therapeutics?

What is the APC / publication cost?

What is the acceptance rate?